This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acorda Therapeutics Inc (ACOR)

: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 492.66M 401.48M 336.43M 305.81M
Cost of Sales 92.93M 64.25M 57.07M 48.53M
Gross Operating Profit 399.73M 337.23M 279.36M 257.29M
Selling, General, and Administrative Expenses 205.63M 201.81M 185.54M 168.69M
Research & Development 149.21M 73.47M 53.88M 53.88M
Operating Income before D & A (EBITDA) 44.89M 61.94M 39.94M 34.71M
Depreciation & Amortization n.a. 16.36M 9.57M 9.11M
Interest Income n.a. 674.00K 668.00K 552.00K
Other Income - Net -14.62M 232.00K 0.00 -6.00K
Special Income / Charges -10.90M -9.19M 0.00 0.00
Total Income Before Interest Expenses (EBIT) 19.37M 37.30M 31.03M 26.15M
Interest Expense 0.00 9.29M 2.17M 1.88M
Pre-Tax Income 19.37M 28.01M 28.86M 24.27M
Income Taxes 8.31M 10.34M 12.42M -130.69M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 11.06M 17.67M 16.44M 154.96M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 11.06M 17.67M 16.44M 154.96M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 11.06M 17.67M 16.44M 154.96M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
21.96M 26.86M 16.44M 154.96M
Preferred Dividends
Net Income Available To Common 0.00 17.67M 16.44M 154.96M
Basic EPS from Continuing Ops. 0.26 0.43 0.41 3.93
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.26 0.43 0.41 3.93
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.26 0.43 0.41 3.93
Basic Normalized Net Income/Share 0.52 0.65 0.41 3.93
EPS fr Continuing Ops. 0.25 0.42 0.39 3.84
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.25 0.42 0.39 3.84
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 0.25 0.42 0.39 3.84
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.50 0.63 0.39 3.84
Dividends Paid per Share 0.00 0.00 0.00 0.00
ACOR News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ACOR Acorda Therapeutics Inc

Chart of ACOR

Analysts Ratings for ACOR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ACOR ANALYST REPORT

ACOR Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs